BioSpace News Archive

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, announced that the Company will participate in two investor conferences in May.

Arch Therapeutics, Inc. announced that the Company’s first commercial product, AC5® Advanced Wound System, will be featured at the 2024 Symposium on Advanced Wound Care Spring Meeting, which takes place at Orlando Marriott World Center, Orlando, from May 14-18, 2024.

Agios Pharmaceuticals, Inc., a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, announced that the company is scheduled to present at the BofA Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 11:40 a.m. ET.

Cara Therapeutics, Inc., a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, announced the Company will report first quarter 2024 financial results on Monday, May 13, 2024, after the U.S. markets close.

Omega Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.

Inari Medical, Inc. announced its management team will present at the upcoming Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024, at 11:20 AM Pacific Time.

EyePoint Pharmaceuticals, Inc. announced topline results of its Phase 2 PAVIA clinical trial evaluating DURAVYU™, previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy.

Annovis Bio, Inc. announced that Maria Maccecchini, Founder, President, and CEO of Annovis, issued a letter to stockholders providing a review of Phase II/III data from its Alzheimer’s study and sharing next steps.

Spectral Medical Inc., a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock.

Zimmer Biomet Holdings, Inc., a global medical technology leader, published its 2023 Sustainability Report which provides an overview of the company’s environmental, social and governance program, progress, and accomplishments.